VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday

VYNE Therapeutics (NASDAQ:VYNEGet Free Report) is projected to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.14 million for the quarter.

VYNE Therapeutics Price Performance

VYNE stock opened at $2.55 on Thursday. The company has a fifty day moving average price of $2.83 and a two-hundred day moving average price of $2.48. VYNE Therapeutics has a one year low of $1.57 and a one year high of $4.30. The stock has a market cap of $37.62 million, a price-to-earnings ratio of -2.97 and a beta of 1.28.

Analysts Set New Price Targets

A number of equities analysts have commented on VYNE shares. BTIG Research started coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $5.75 price objective on shares of VYNE Therapeutics in a research report on Wednesday, February 19th.

View Our Latest Stock Report on VYNE

Insider Activity

In other VYNE Therapeutics news, Director Patrick G. Lepore bought 15,000 shares of VYNE Therapeutics stock in a transaction dated Wednesday, January 15th. The stock was bought at an average price of $2.92 per share, with a total value of $43,800.00. Following the completion of the transaction, the director now owns 51,472 shares in the company, valued at $150,298.24. The trade was a 41.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.80% of the stock is currently owned by company insiders.

About VYNE Therapeutics

(Get Free Report)

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.

Read More

Earnings History for VYNE Therapeutics (NASDAQ:VYNE)

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.